SIRT1 and inflammatory bowel disease: In this regard, a down-regulation has been described of the AMPK/SIRT-1 axis in the gut of IBD patients as well as in mice with an IBD-like colitis, also reporting the abrogation of pro-inflammatory cytokine production and a reduction of the intestinal damages following the treatment of mice with an AMPK or SIRT-1 activators [11,34].